Prevention and management of infectious complications in IBD

Digestive Diseases

Volumn 30, Issue 4, 2012, Pages 408-414

  Rahier, Jean François ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Opportunistic infections; Prevention; Vaccination

Indexed keywords

ACICLOVIR; ALBENDAZOLE; COTRIMOXAZOLE; VALACICLOVIR;

ARTICLE; CHEMOPROPHYLAXIS; DISEASE PREDISPOSITION; ENTERITIS; HEALTH EDUCATION; HUMAN; IMMUNOCOMPROMISED PATIENT; MORBIDITY; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; VACCINATION;

HUMANS; INFLAMMATORY BOWEL DISEASES; OPPORTUNISTIC INFECTIONS; PATIENT EDUCATION AS TOPIC; RISK FACTORS; TRAVEL; VACCINATION;

EID: 84863890470     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000338143     Document Type: Article

References (31)

1. Cosnes J, Nion-Larmurier I, Beaugerie L, et al: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241.
2. Rutgeerts P, Van Assche G, Vermeire S: Review article: infliximab therapy for inflammatory bowel disease -seven years on. Aliment Pharmacol Ther 2006; 23: 451-463.
3. Symmers WS: Opportunistic infections. The concept of 'opportunistic infections'. Proc R Soc Med 1965; 58: 341-346.
4. Lichtenstein GR, Feagan BG, Cohen RD, et al: Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-630.
5. Lichtenstein GR, Diamond RH, Wagner CL, et al: Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-226.
6. Marehbian J, Arrighi HM, Hass S, et al: Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009; 104: 2524-2533.
7. Toruner M, Loftus EV Jr., Harmsen WS, et al: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936.
8. Kovacs JA, Masur H: Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1416-1429.
9. Colombel JF, Loftus EV Jr., Tremaine WJ, et al: The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
10. Cottone M, Kohn A, Daperno M, et al: Age is a risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 30-35.
11. Gavazzi G, Krause KH: Ageing and infection. Lancet Infect Dis 2002; 2: 659-666.
12. Krok KL, Lichtenstein GR: Nutrition in Crohn disease. Curr Opin Gastroenterol 2003; 19: 148-153.
13. Schoepfer AM, Flogerzi B, Fallegger S, et al: Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 2799-2806.
14. Papay P, Eser A, Winkler S, et al: Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 84-90.
15. Rahier JF, Ben Horin S, Chowers Y, et al: European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. JCC 2009; 3: 47-91.
16. Fardet L, Genereau T, Poirot JL, et al: Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect 2007; 54: 18-27.
17. Loras C, Gisbert JP, Minguez M, et al: Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59: 1340-1346.
18. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al: Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549-558.
19. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK: General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2006; 55: 1-48.
20. Roush SW, Murphy TV. Historical comparisons of morbidity and mortality for vaccinepreventable diseases in the United States. JAMA 2007; 298: 2155-2163.
21. Henning KJ, White MH, Sepkowitz KA, et al: A national survey of immunization practices following allogeneic bone marrow transplantation. JAMA 1997; 277: 1148-1151.
22. Sands BE, Cuffari C, Katz J, et al: Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 677-692.
23. Moses J, Alkhouri N, Shannon A, et al: Hepatitis B immunity and response to booster immunization in children with inflammatory bowel disease treated with Infliximab. Gastroenterology 2011; 140(suppl 1):S893.
24. Chaparro M, Rodriguez Nogueiras A, et al: Comparative study to evaluate the effectiveness of two different vaccination protocols against hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients. Gastroenterology 2011; 140(suppl 1):S587-S588.
25. Lu Y, Ashworth LA, Bousvaros A, et al: Immune response to human papillomavirus vaccine (Gardasil) in girls and young women with inflammatory bowel disease. Gastroenterology 2011; 140(suppl 1):S158-S159.
26. Mamula P, Markowitz JE, Piccoli DA, et al: Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 851-856.
27. Lu Y, Jacobson DL, Ashworth LA, et al: Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009; 104: 444-453.
28. Cullen G, Bader C, Korzenik JR, et al: Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 2012; 61: 385-391.
29. Rahier JF, Papay P, Salleron J, et al: H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 2011; 60: 456-462.
30. Melmed GY, Agarwal N, Frenck RW, et al: Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 148-154.
31. Fiorino G, Naccarato P, Szabo H, et al: Effect of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Gastroenterology 2011; 140(suppl 1):S158.